ReviewCureus2025

Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Chao Yuan Li Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.